Abstract
The vitamin D receptor (VDR) is an endocrine member of the nuclear receptor superfamily and binds the biologically most active vitamin D metabolite, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3). The VDR ligandbinding domain is a molecular switch, since its ligand-triggered interactions with corepressor and coactivator proteins are the central molecular events of nuclear 1α,25(OH)2D3 signaling. 1α,25(OH)2D3 analogues have been developed with the goal to improve the biological profile of the natural hormone for a therapeutic application either in hyperproliferative diseases, such as psoriasis and different types of cancer, or in bone disorders, such as osteoporosis. Most of the analogues described to date are agonists, with a few having been identified as antagonists. Only the two side chain analogue Gemini and some of its derivatives act under restricted conditions as inverse agonists. In this review we discuss the molecular mechanisms of these different type of analogues based on crystal structure data, molecular dynamics simulations and biochemical assays.
Keywords: Nuclear receptor signaling, vitamin D, vitamin D analogues, vitamin D receptor, coactivator proteins, corepressor proteins
Current Topics in Medicinal Chemistry
Title: Detailed Molecular Understanding of Agonistic and Antagonistic Vitamin D Receptor Ligands
Volume: 6 Issue: 12
Author(s): Carsten Carlberg and Ferdinand Molnar
Affiliation:
Keywords: Nuclear receptor signaling, vitamin D, vitamin D analogues, vitamin D receptor, coactivator proteins, corepressor proteins
Abstract: The vitamin D receptor (VDR) is an endocrine member of the nuclear receptor superfamily and binds the biologically most active vitamin D metabolite, 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3). The VDR ligandbinding domain is a molecular switch, since its ligand-triggered interactions with corepressor and coactivator proteins are the central molecular events of nuclear 1α,25(OH)2D3 signaling. 1α,25(OH)2D3 analogues have been developed with the goal to improve the biological profile of the natural hormone for a therapeutic application either in hyperproliferative diseases, such as psoriasis and different types of cancer, or in bone disorders, such as osteoporosis. Most of the analogues described to date are agonists, with a few having been identified as antagonists. Only the two side chain analogue Gemini and some of its derivatives act under restricted conditions as inverse agonists. In this review we discuss the molecular mechanisms of these different type of analogues based on crystal structure data, molecular dynamics simulations and biochemical assays.
Export Options
About this article
Cite this article as:
Carlberg Carsten and Molnar Ferdinand, Detailed Molecular Understanding of Agonistic and Antagonistic Vitamin D Receptor Ligands, Current Topics in Medicinal Chemistry 2006; 6 (12) . https://dx.doi.org/10.2174/156802606777864908
DOI https://dx.doi.org/10.2174/156802606777864908 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issues: Advances in Developmental and Reproductive Toxicology)
Current Pharmaceutical Design Adipoparacrinology of Atherosclerosis: Evidence Updated
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Indirect Production of No Carrier Added (NCA) <sup>177</sup>Lu from Irradiation of Enriched <sup>176</sup>Yb: Options for Ytterbium/Lutetium Separation
Current Radiopharmaceuticals Does Vitamin D Deficiency Epidemic Parallel with Allergy and Asthma Epidemic?
Mini-Reviews in Medicinal Chemistry Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Analytical Methods for Quantitation of Prenylated Flavonoids from Hops
Current Analytical Chemistry A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Introduction: Hepatocyte Growth Factor and Met Receptor, from Discovery to Therapeutic Implications
Current Signal Transduction Therapy Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors
Current Drug Metabolism Matrix Metalloproteinases in Cancer Metastasis: Molecular Targets for Prostate Cancer Prevention by Green Tea Polyphenols and Grape Seed Proanthocyanidins
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial: Recent developments in the Application of Separation and Hyphenated Techniques in Current Diagnostic Challenges
Current Medicinal Chemistry Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology Peroxisome Proliferator-Activated Receptor (PPAR) in Regenerative Medicine: Molecular Mechanism for PPAR in Stem Cells’ Adipocyte Differentiation
Current Stem Cell Research & Therapy When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts
Current Drug Targets Stearoyl-CoA Desaturase-1 and the Metabolic Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Use of Radiopharmaceuticals for Diagnosis, Treatment, and Follow-Up of Differentiated Thyroid Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Endogenous Factors in the Recovery of Reproductive Function After Testicular Injury and Cancer
Current Molecular Medicine